In the past decade, there have been significant breakthroughs in cancer research through advances in immuno-oncology, a therapeutic approach that uses the body's immune system to fight cancer. Sales of the new immuno-oncology drugs launched last year have crossed $1bn. This issue was brought back into the public focus again after President Obama’s State of the Union address reflecting renewed interest in the innovations in cancer research and implications for investors.
Much is changing in cancer research and scientific progress in diagnosis and treatment, which has led to a better outlook for cancer patients. Pharmaceutical companies with exposure to oncology have offered better earnings growth and high returns on capital and smaller biotech companies with no prior history have also entered the fray. This session will address the questions on top of investors’ minds including anticipated advancement in cancer research and immunotherapy, sector views and investment implications as well as due-diligence guidelines for investors.
This event will:
Who should attend?
Portfolio managers and research analysts, hedge funds, mutual funds, private equity firms and service providers such as attorneys, consultants, and rating agency personnel.
NYSSA expects all attendees to comply with NYSSA’s Code of Conduct while attending NYSSA events or meetings. NYSSA expressly reserves the right, in its sole discretion, to grant or deny access to any individual, or to expel any individual from any NYSSA event or meeting.
The New York Society of Security Analysts, Inc. (“NYSSA”) is not a Registered Investment Advisor, Broker/Dealer, Financial Analyst, Financial Bank, Securities Broker, or Financial Planner. While NYSSA seeks to present accurate and reliable information, NYSSA does not endorse, approve, or certify such information, nor does it warrant or guarantee the accuracy, completeness, efficacy, timeliness, or fitness of such information for any particular purpose. Information presented may or may not be current as of the date of the presentation, and NYSSA has no duty to update and maintain the information, reports, or statements made during events.
The information presented is provided for information purposes only, and is not intended to be and does not constitute financial advice, investment advice, trading advice, or any other advice, is general in nature, and is not specific to you. None of the information presented is intended as an offer or solicitation of an offer to buy or sell, or as a recommendation, endorsement, or sponsorship of any security, company, or fund. NYSSA is not responsible for any investment decision made by you.
You should not make any financial, investment, trading or other decision based upon any of the information presented at NYSSA without undertaking your own independent due diligence and consulting with a qualified and registered securities professional. You understand that your use of any of the information presented at NYSSA is at your own risk.
There is a substantial amount of risk in trading securities, and the possibility exists that you can lose all, most or a portion of your capital. NYSSA does not, cannot, and will not assess or guarantee the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The securities mentioned in any NYSSA presentation may not be suitable for investors depending on their specific investment objectives and financial condition.
Wednesday, February 24, 2016
6:00 – 6:15 p.m. Check-in
6:15 – 7:30 p.m. Presentation
7:30 – 8:00 p.m. Networking
730 3rd Ave
New York, NY 10017
CRI Member: $15
No walk-ins or students will be permitted at this event.
NYSSA reserves right to decline admission / refund registration costs
Jill O’Donnell-Tormey, Ph.D., CEO and Director of Scientific Affairs, Cancer Research Institute (CRI)
Michael Kalos, Chief Scientific Officer of Cancer Immunobiology, Eli Lilly
Brad Loncar, Portfolio Manager, Loncar Investments
Dr. Joseph Kim, CEO, Inovio
Reni J. Benjamin, Ph.D, Senior Vice-President, Equity Research, Biotechnology
Yacov Arnopolin, Trustee, Cancer Research Institute
Deepika Sharma, CFA
Sandra LaBaugh, CFA
Albert C. Yuen, CFA
If you are unable to register for this event online, please call (212) 541-4530 for assistance.
Register via Mail/Fax
Policies and Procedures